why choose us

First received: October 10, 2023

Clinical Trial: Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Biochemically Recurrent Prostate Carcinoma

Study Type: INTERVENTIONAL


Official Title: Phase 1 Trial to Determine Safety and Feasibility in Treating Biochemical Recurrence Post-Prostatectomy With PSMA PET Guided External Beam Radiotherapy Followed by Consolidative Radioligand Therapy

Brief Summary: This phase I trial tests the safety, side effects and best dose of radioligand therapy (lutetium Lu 177 PSMA-10.1 [177Lu-rhPSMA-10.1])after prostate specific membrane antigen (PSMA) positron emission tomography (PET)-guided external beam radiotherapy in treating post-prostatectomy patients with prostate cancer that has come back after a period of improvement (recurrent).In this study, radioligand therapy is a radioactive drug called 177Lu-rhPSMA-10.1.It works by binding to PSMA-expressing prostate tumor cells and…

Read more